Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Home - The Pharma Times | Pharma & Health Care News Portal
Thursday, April 18, 2024

Ajeenkya D Y Patil Healthcare Awards an Approximate 100 Mn USD...

New Delhi, August 06, 2021: The domestic healthcare player - Ajeenkya D Y Patil Group in a step towards concreting their aspirations to be a...

8-year-old child travels 1500 km to receive life-saving liver transplant at...

Bangalore, September 29, 2020: In the midst of the Covid-19 pandemic, Aster RV Hospital has helped 8-year-old Prerna receive a lifesaving liver transplant through...

Biotechnology

IT & Software Support

Appointments

Swiss based Pharma Veteran, Balasubramanian Srinivasan (Srini Srinivasan) joins TAKE Solutions Board as an...

Chennai, December 07, 2019: TAKE Solutions Ltd. , a globally recognized domain intensive services provider in Life Sciences, today announced the appointment of Srini Srinivasan...

Awards

Financial Results

Approvals

Biophore receives sub-license from MPP to manufacture and market molnupiravir for COVID treatment

Can market in India and 104 other countries Has also received DCGI regulatory license for Indian market Licenses applicable for both API and...

Clinical Trails

Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival...

Berlin, January 3, 2013 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase III trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting. Effective treatment options are urgently needed for patients with RAI-refractory differentiated thyroid cancer,” said Dimitris Voliotis, MD, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients.

Bulk Drug

Health Care

Alternative Medicine

Eye Care

Digital Eye Strain Affects Children Now More than Ever

By  Dr. Anand Balasubramaniam, Senior Consultant Cornea, Sankara Eye hospital Bangalore The current lock down due to COVID-19 pandemic has led to the biggest self-isolation...

Product News

Media Partners

Spotlight

Investments

Packaging

Latest News

Hester Biosciences Ltd encouraging Women to Lead

All the three Plant Heads of India, Nepal, Tanzania are women  Ahmedabad, March 04, 2022: Hester is an organisation that has always encouraged women's leadership, diversity,...

Seth Anandram Jaipuria School, Ghaziabad, conducts ‘Virtual Award Ceremony’ for students

New Delhi, May 10, 2022 : Seth Anandram Jaipuria School, Vasundhara, Ghaziabad, organised a 'Virtual Award Ceremony' on April 30, 2022, to acknowledge and...

New Lease on Life at 49: Kiran Kumar’s Journey to Recovery with a Complex...

Bengaluru, january 17, 2024 : At 49, Kiran Kumar's daily walks felt like climbing mountains. Suffering from an extensive anterior wall myocardial infarction (MI) leading to...

Dental Care

Tips to maintain oral health!

By Dr.MS Prasad, Dental Surgeon, Columbia Asia Referral Hospital Yeshwanthpur It has been said that a person’s real happiness begins from the plate and is...

Hospital Management

Drug Discovery & Development

Suppliers

Technology

Companies

6th Annual Pharma Project & Portfolio Management 2023

EVENT NAME; 6th Annual Pharma Project & Portfolio Management 2023. EVENT SHORT DESCRIPTION: The 6th Annual Pharma Project & Portfolio Management 2023 will be focusing...

Marketing

Our Partners

Machinery & Equipments